PFE vs BMY — Key Metrics
| Metric | PFE (PFIZER INC) | BMY (BRISTOL MYERS SQUIBB CO) |
|---|---|---|
| Price | 28.06 | 59.56 |
| Market Cap | 159.94 Billion | 121.75 Billion |
| P/E (TTM) | 39.52 | 13.15 |
| P/B (Quarterly) | 1.921 | 5.362 |
| P/S (TTM) | 2.51 | 2.43 |
| Net Profit Margin (TTM) | 6.3 | 18.5 |
| Gross Margin (TTM) | 73.4 | 69.2 |
| ROE (TTM) | 4.6 | 43.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Greatly Outperform
Recommendation Summary
Both stocks are projected to significantly outperform the market over the next year. If you have to make a choice, Upfront Recommendation: PFE.
Financial Metrics
| PFE | Metrics | BMY |
|---|---|---|
| $28.06 | Price | $59.56 |
| — | Market Capitalization | — |
| 39.52 | Price to Earnings Ratio | 13.15 |
| 2.51 | Price to Sales | 2.43 |
| 13.57 | Price to FCF Ratio | 13.11 |
| 3.43 | Price to Gross Profit | 3.51 |
| 13.88 | Price to R&D | 11.53 |
| 3.55 | Price to Current Assets | 4.09 |
PFE vs BMY at a glance
Pfizer INC (PFE) and Bristol Myers Squibb CO (BMY) are both Drug Manufacturers - General companies in the Healthcare sector. PFE is the larger, at $159.9 billion in market value against $121.7 billion for BMY, about 1.3 times the size.
On trailing-twelve-month figures, PFE trades at 39.5 times trailing earnings and BMY at 13.2; net profit margins are 6.3% and 18.5%.
The Upfront Investment model currently rates both Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.